retatrutide clinical trial obesity ESC 2024: improves lipid and cardiovascular risk profile in Phase II VisualAbstract: Retatrutide reduces body weight

Important safety considerations include a boxed warning for medullary thyroid carcinoma risk, monitoring for pancreatitis (severe abdominal pain), gallbladder disease, and potential hypoglycemia when used with insulin or sulfonylureas

The point is not perfection

It is not intended as medical advice and should not be used as a substitute for professional medical guidance

Although formulations vary, most GLP-1 patches contain similar ingredients

Increased risk of pulmonary aspiration (food getting into your lungs) during surgery or other procedures that use anesthesia or deep sedation due to delayed gastric emptying

Youve heard of the popular glucagon-like peptide-1 (GLP-1) receptor agonist drug semaglutide (Ozempic, Wegovy) and GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound)